{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:43Z","timestamp":1792099603122,"version":"4.4.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012431","name":"Celldex Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaad.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:23:55Z","timestamp":1755620635000},"page":"1596-1599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of barzolvolimab, an anti\u2013KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study"],"prefix":"10.1016","volume":"93","author":[{"given":"Martin","family":"Metz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moiin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Nattkemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rogalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hawthorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Androniki","family":"Bili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Meltzer-Podolske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.08.022_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/13543784.2013.740010","article-title":"Therapeutic targeting of c-KIT in cancer","volume":"22","author":"Ashman","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2025.08.022_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9390","article-title":"Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation","volume":"387","author":"Liu","year":"2025","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jaad.2025.08.022_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2025.08.022_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.clindermatol.2025.03.013","article-title":"Prurigo nodularis in 2025: current and emerging treatments","author":"Brooks","year":"2025","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.08.022_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/bjd\/ljae453","article-title":"Association of sleep disturbance and itch intensity with quality of life impairment and disease severity in prurigo nodularis","volume":"192","author":"Lu","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225026489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225026489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:23:53Z","timestamp":1791879833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225026489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0190962225026489"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.022","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of barzolvolimab, an anti\u2013KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}